205 related articles for article (PubMed ID: 32396709)
1. Exploring Ovarian Cancer Cell Resistance to Rhenium Anticancer Complexes.
Marker SC; King AP; Swanda RV; Vaughn B; Boros E; Qian SB; Wilson JJ
Angew Chem Int Ed Engl; 2020 Aug; 59(32):13391-13400. PubMed ID: 32396709
[TBL] [Abstract][Full Text] [Related]
2. Exploring ovarian cancer cell resistance to rhenium anticancer complexes.
Marker SC; King AP; Swanda RV; Vaughn B; Boros E; Qian SB; Wilson JJ
Angew Chem Weinheim Bergstr Ger; 2020 Aug; 132(32):13493-13502. PubMed ID: 34366495
[TBL] [Abstract][Full Text] [Related]
3. Exploring the In Vivo and In Vitro Anticancer Activity of Rhenium Isonitrile Complexes.
Marker SC; King AP; Granja S; Vaughn B; Woods JJ; Boros E; Wilson JJ
Inorg Chem; 2020 Jul; 59(14):10285-10303. PubMed ID: 32633531
[TBL] [Abstract][Full Text] [Related]
4. A Rhenium Isonitrile Complex Induces Unfolded Protein Response-Mediated Apoptosis in Cancer Cells.
King AP; Marker SC; Swanda RV; Woods JJ; Qian SB; Wilson JJ
Chemistry; 2019 Jul; 25(39):9206-9210. PubMed ID: 31090971
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial Synthesis to Identify a Potent, Necrosis-Inducing Rhenium Anticancer Agent.
Konkankit CC; Vaughn BA; MacMillan SN; Boros E; Wilson JJ
Inorg Chem; 2019 Mar; 58(6):3895-3909. PubMed ID: 30793900
[TBL] [Abstract][Full Text] [Related]
6. X-Ray fluorescence microscopy reveals that rhenium(i) tricarbonyl isonitrile complexes remain intact in vitro.
Konkankit CC; Lovett J; Harris HH; Wilson JJ
Chem Commun (Camb); 2020 Jun; 56(48):6515-6518. PubMed ID: 32432584
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Anticancer Activity and in Vivo Biodistribution of Rhenium(I) Tricarbonyl Aqua Complexes.
Knopf KM; Murphy BL; MacMillan SN; Baskin JM; Barr MP; Boros E; Wilson JJ
J Am Chem Soc; 2017 Oct; 139(40):14302-14314. PubMed ID: 28948792
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
[TBL] [Abstract][Full Text] [Related]
9. 3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of taxol resistant human ovarian cancer by inhibiting multidrug resistance (MDR) proteins function.
Jin L; Yingchun W; Zhujun S; Yinan W; Dongchen W; Hui Y; Xi Y; Wanzhou Z; Buluan Z; Jinhua W
Biomed Pharmacother; 2019 Aug; 116():108992. PubMed ID: 31129513
[TBL] [Abstract][Full Text] [Related]
10. Systematically altering the lipophilicity of rhenium(I) tricarbonyl anticancer agents to tune the rate at which they induce cell death.
Konkankit CC; Vaughn BA; Huang Z; Boros E; Wilson JJ
Dalton Trans; 2020 Nov; 49(45):16062-16066. PubMed ID: 32319485
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.
Aird RE; Cummings J; Ritchie AA; Muir M; Morris RE; Chen H; Sadler PJ; Jodrell DI
Br J Cancer; 2002 May; 86(10):1652-7. PubMed ID: 12085218
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
[TBL] [Abstract][Full Text] [Related]
13. MDR gene expression analysis of six drug-resistant ovarian cancer cell lines.
Januchowski R; Wojtowicz K; Sujka-Kordowska P; Andrzejewska M; Zabel M
Biomed Res Int; 2013; 2013():241763. PubMed ID: 23484165
[TBL] [Abstract][Full Text] [Related]
14. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
[TBL] [Abstract][Full Text] [Related]
15. Physcion-8-O-β-d-glucoside interferes with the nuclear factor-κB pathway and downregulates P-glycoprotein expression to reduce paclitaxel resistance in ovarian cancer cells.
Li X; He Y; Wei L; Zhang J; Li X; Cui W; Zhang S
J Pharm Pharmacol; 2021 Mar; 73(4):545-552. PubMed ID: 33793827
[TBL] [Abstract][Full Text] [Related]
16. Synthetic paclitaxel-octreotide conjugate reverses the resistance of paclitaxel in A2780/Taxol ovarian cancer cell line.
Shen Y; Zhang XY; Chen X; Fan LL; Ren ML; Wu YP; Chanda K; Jiang SW
Oncol Rep; 2017 Jan; 37(1):219-226. PubMed ID: 27878277
[TBL] [Abstract][Full Text] [Related]
17. The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers.
Collery P; Veena V; Harikrishnan A; Desmaele D
Invest New Drugs; 2019 Oct; 37(5):973-983. PubMed ID: 30632005
[TBL] [Abstract][Full Text] [Related]
18. Dinuclear phosphorescent rhenium(I) complexes as potential anticancer and photodynamic therapy agents.
Pan ZY; Cai DH; He L
Dalton Trans; 2020 Aug; 49(33):11583-11590. PubMed ID: 32766642
[TBL] [Abstract][Full Text] [Related]
19. Anticancer effects of 15d-prostaglandin-J2 in wild-type and doxorubicin-resistant ovarian cancer cells: novel actions on SIRT1 and HDAC.
de Jong E; Winkel P; Poelstra K; Prakash J
PLoS One; 2011; 6(9):e25192. PubMed ID: 21957481
[TBL] [Abstract][Full Text] [Related]
20. Necrosis-Inducing High-Valent Oxo-Rhenium(V) Complexes with Potent Antitumor Activity: Synthesis, Aquation Chemistry, Cisplatin Cross-Resistance Profile, and Mechanism of Action.
Das S; Joshi P; Patra M
Inorg Chem; 2023 Dec; 62(48):19720-19733. PubMed ID: 37974075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
